• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Hypercalcemia - Pipeline Review, Q2 2011 - Product Image

Hypercalcemia - Pipeline Review, Q2 2011

  • ID: 1816149
  • May 2011
  • 47 pages
  • Global Markets Direct

Hypercalcemia - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Hypercalcemia - Pipeline Review, Q2 2011', provides an overview of the Hypercalcemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercalcemia. 'Hypercalcemia - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypercalcemia.
- A review of the Hypercalcemia products under development by companies and universities/research institutes based on information derived READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypercalcemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercalcemia
Hypercalcemia Therapeutics under Development by Companies
Hypercalcemia Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Hypercalcemia Therapeutics - Products under Development by Companies
Hypercalcemia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hypercalcemia Therapeutics Development
Amgen Inc.
Genta Incorporated
Metabolex, Inc
Med Discovery SA
Hypercalcemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Xgeva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G4544 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aminopterin + Asparaginase + Cyclophosphamide + Cytarabine + Daunomycin + Dexamethasone + Hydrocortisone + 6-Mercaptopurine + Methotrexate + 6-Thioguanine + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aminopterin + Asparaginase + Cyclophosphamide + Cytarabine + Daunomycin + Dexamethasone + Hydrocortisone + 6-Mercaptopurine + Methotrexate + 6-Thioguanine + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldesleukin + Therapeutic Autologous Lymphocytes + Zoledronic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDAB16 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercalcemia Therapeutics – Drug Profile Updates
Hypercalcemia - Featured News
Dec 02, 2009: Genta to Support Initiation of New Clinical Trial using Ganite as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis
Jun 04, 2007: Phase 2 Clinical Results of Ganite® Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Mar 07, 2007: Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite® and Genasense®
Mar 02, 2006: Randomized Trial Shows Ganite® Effective When Compared with A Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
Dec 23, 2004: NPS Completes $175 Million Note Offering Backed by Sensipar Royalties
Dec 05, 2004: Ganite® Activity in Patients with Advanced Non-Hodgkin's Lymphoma Presented at Hematology Meeting
Jul 30, 2004: Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion for Approval in Europe
Apr 08, 2004: Sensipar Pivotal Studies in over 700 Patients Published in New England Journal of Medicine
Mar 25, 2004: GenasenseTM and GaniteTM Featured in Presentations at the Annual Meeting of the American Association for Cancer Research
Mar 09, 2004: NPS Pharmaceuticals Announces Approval of Sensipar by U.S. FDA.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hypercalcemia, Q2 2011
Products under Development for Hypercalcemia – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Amgen Inc., 2011
Genta Incorporated, 2011
Metabolex, Inc, 2011
Med Discovery SA, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Hypercalcemia Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Hypercalcemia, Q2 2011
Products under Development for Hypercalcemia – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos